Please login to the form below

Not currently logged in
Email:
Password:

Type II diabetes

This page shows the latest Type II diabetes news and features for those working in and with pharma, biotech and healthcare.

Novo's oral semaglutide ‘safe and well-tolerated’

Novo's oral semaglutide ‘safe and well-tolerated’

PIONEER 1, oral semaglutide’s first phase III study, investigated its safety and efficacy in in adults with type 2 diabetes who took 3, 7 and 14mg doses of the drug ... II clinical trial in type 2 diabetes”.

Latest news

  • Forming a picture of health Forming a picture of health

    Noting it’s an “overarching issue”that can cause cancer, type II diabetes, fatty liver disease and many additional health problems, which “ultimately will cost more to treat if obesity ... A school-based education programme, GEN100 covers

  • FDA panel backs CV claims for Novo Nordisk's Victoza FDA panel backs CV claims for Novo Nordisk's Victoza

    Cardiovascular disease is the number one cause of death for people with type II diabetes, and [the EMDAC's] discussion is an important reminder that there is an unmet need to ... The positive vote from EMDAC puts us one step closer to expanding our

  • Sanofi and Lexicon collaborate on new medication for diabetes Sanofi and Lexicon collaborate on new medication for diabetes

    Sotagliflozin has previously shown encouraging results in phase II studies for type 1 diabetes, including reduction of blood sugar (HBA1C) improvement in glycaemic variability and reduced mealtime insulin dose compared with ... placebo. Phase II studies

  • NICE backs use of anti-cholesterol drug Ezetrol NICE backs use of anti-cholesterol drug Ezetrol

    Ezetrol was backed to treat adults with hypercholesterolaemia when statins cannot be taken and when they require lipid modification therapy for prevention of cardiovascular disease (CVD), have both type II diabetes ... compared with no treatment in

  • J&J's Invokana receives new FDA safety warning J&J's Invokana receives new FDA safety warning

    Invokana is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for type II diabetes and works by causing blood sugar to leave the body primarily through urine. ... The companies' Jardiance (empaglifozin) was just last month able to claim itself as

More from news
Approximately 1 fully matching, plus 81 partially matching documents found.

Latest Intelligence

  • Digital health Digital health

    anecdotal evidence that it can reverse type II diabetes.

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    This broad category has seen considerable activity in the last decade driven by two successive class introductions - the DPP4s and SGLT2s; both licensed for type II diabetes. ... Complements are products that are often used together. Sometimes this

  • Pharma deals during November 2013 Pharma deals during November 2013

    for type II diabetes, (projected sales of $221.6m in 2015). ... China, Hong Kong, Malaysia, Singapore and Australia in certain therapeutic fields, namely cardiovascular, renal and diabetes applications.

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    Targets for Type II diabetes – 3 products. 430. Okairos/ GSK. ... Company acquisition . Vaccines in phase I and II. 250. Alexza/ Teva. Licence, supply US.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics